Introduction

Rhinitis

Rhinitis is an inflammatory disease of the nose and is reported to affect up to 40% of the population.
It is the fifth most common chronic disease in the United States.
The most common and impactful symptoms of rhinitis are congestion and rhinorrhoea.

Allergic Rhinitis

Allergic rhinitis accounts for up to 65% of all rhinitis patients. Allergic rhinitis is an immune response to an exposure to allergens, such as airborne plant pollens, pet dander or dust.

Non-allergic Rhinitis

Non-allergic rhinitis is the occurrence of common rhinitis symptoms of congestion and rhinorrhoea. As non-allergic rhinitis is not an immune response, it’s symptoms are not normally seasonal and are often more persistent.

Current Treatments

Rhinitis a condition in which the sinus and nasal passages become inflamed.
The symptoms of rhinitis include a runny nose, sneezing, and nasal itching and congestion.

Neurent Icon

Pharmacotherapy

Allergen avoidance and pharmacotherapy are relatively effective in the majority of mild cases, but these medications need to be taken on a long-term basis, incurring costs and side effects and often have suboptimal efficacy. Therefore, substantial portions of rhinitis patients are candidates for surgical treatments.

Neurent Icon

Surgical Therapy

There are two modern surgical options: the delivery of thermal energy to the inflamed soft tissue, resulting in scarring and temporary volumetric reduction of the tissue to improve nasal airflow; and microdebrider resection of the inflamed soft tissue, resulting in the removal of tissue to improve nasal airflow. Both options address congestion as opposed to rhinorrhoea and have risks ranging from bleeding and scarring to the use of general anaesthetic.

We have Found

A Better Solution

Our product offering is a minimally invasive hand-held radio-frequency device which ENT surgeons will use to treat patients in an office setting, removing the complications and costs associated with most surgical procedures.

The single use device is introduced through the nostrils into the nasal cavity under direct endoscopic visualisation; where it deploys a micro electrode array that delivers targeted energy to interrupt the autonomic function within the mucosal structures of nasal cavities which will reverse the inflammatory cascade. The device will be used in conjunction with an intelligent radio-frequency generator that is being designed and developed by Neurent Medical in parallel.

We have invested significant effort in determining the ideal, power and controlled energy delivery in order to maximise its impact to the intended target while minimising collateral damage.

Minimally Invasive

Unlike other treatments for rhinitis which often require a surgical procedure, our device is minimally invasive. The procedure can be performed in an office environment under local anesthetic.

Years of Relief

Based on our research into neuronal activity in the nasal cavity and the cellular make up of nasal mucosa, we expect our new treatment to provide long-term symptom relief.

Allergic/Non-allergic Rhinitis

Our low powered RF treatment targets the autonomic supply to the nasal turbinates and will have a positive impact on both allergic and non-allergic rhinitis.

Immediate Impact

Our treatment is accurate with minimal collateral damage to the surrounding tissue. Patients will begin to feel symptom relief immediately following the treatment.

Neurent Icon

Drugs

Currently patients remain on their existing drug treatment plan following a surgical intervention. We fully expect patients to be removed from their pharmacotherapies following this therapy.

Neurent Icon

Safety

Our approach is to ensure we have a profound understanding of the device, its safety profile, and how to optimise its treatment effect. Our R&D program has enabled us to develop specialised RF techniques and confidently define optimal energy dosing ranges to satisfy primary safety concerns.

More

About Us

Neurent Medical Ltd is a privately held, venture backed, Galway (Ireland) based medical device company in the ear, nose and throat market.
Neurent Medical was founded by Brian Shields and David Townley and originated from the BioInnovate Ireland programme at the National University of Ireland, Galway.

Leadership Team

Brian Shields Co-founder & CEO

Brian has a PhD in Applied Computing and an MBA from Ireland’s leading Business School. He worked extensively as a Management Consultant in London and Dublin leading large healthcare service and technology design and implementation programmes across Europe.

David Townley Co-founder & CTO

David has a BEng in Mechanical Engineering and a MSc in Quality & Technology Management with over 16 years’ experience in research and development. He has held senior positions in R&D, programme management and as a technology consultant in Ireland, USA and Australia. He has led multiple medical devices from concept to market in the cardiovascular, endo-surgery, orthopaedic and ophthalmology fields.

Board of Directors

Brian Shields Co-founder & CEO,
Neurent Medical

David Townley Co-founder & CTO,
Neurent Medical

Mark Fletcher Former President,
Medtronic Surgical Technologies

Justin Lynch

Justin Lynch Partner & CFO,
Fountain Healthcare Partners

Work with us

Careers

We currently don't have any open positions at Neurent Medical however, we are always interested in speaking with smart, motivated people. Please contact us below if you would like to introduce yourself.

Say Hello

Contact Us

Neurent Medical is a medical device company based in Galway, Ireland.

Leave this empty:

Neurent Medical

  • No. 1 Oran Point,
    Main Street,
    Oranmore,
    Galway,
    Ireland

General Enquiries

info@neurentmedical.com